Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28878467 | 0.90 | CYP11B2 (0.36) | NOTUM | |
| SCHEMBL16953722 | 0.74 | ESR2 (0.35) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL193944 | 0.73 | ESR2 (0.38) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL21268227 | 0.73 | ESR2 (0.43) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL15352986 | 0.73 | ESR2 (0.34) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL16952341 | 0.73 | ESR2 (0.34) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL15352291 | 0.70 | HTR2C (0.40) | ESR2POLB | |
| SCHEMBL458384 | 0.68 | DRD2 (0.36) | ESR2DRD2ESR1CYP3A4CYP2C9 | |
| SCHEMBL21268306 | 0.68 | ESR2 (0.31) | ESR2 | |
| SCHEMBL15352612 | 0.68 | ESR2 (0.34) | ESR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341357-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-07-04 | — | — | EP | claimed |
| WO-2017037595-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-03-09 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-10336688-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20190144375-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10189775-B2 | Carbocyclic compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180237382-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-3341357-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-07-04 | — | — | EP | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017037595-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-03-09 | — | — | WO | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| CN-104326952-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-02-04 | — | — | CN | disclosed |
| CN-104277004-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-01-14 | — | — | CN | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336688-B2 | Carbocyclic compounds as ROR gamma modulators | RORB, RORC, RORA | ESR2 101/4885POLB 1522/4885DRD2 1167/4885 |
| US-10189775-B2 | Carbocyclic compounds as ROR gamma modulators | RORB, RORC, RORA | ESR2 101/4885POLB 1522/4885DRD2 1167/4885 |
| US-20190144375-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORC, RORA | ESR2 114/4885POLB 1658/4885DRD2 1313/4885 |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | ESR2 3874/4885POLB 1257/4885DRD2 1629/4885 |
| US-20180237382-A1 | NOVEL CARBOCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORC, RORA | ESR2 114/4885POLB 1658/4885DRD2 1313/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | ESR2 3874/4885POLB 1257/4885DRD2 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.